HANXBIO-B (03378) Debuts with 9.69% Drop in Early Trading; Core Product HX009 Undergoes Three Clinical Trials in China

Stock News12-23 09:40

HANXBIO-B (03378) made its market debut today, with shares priced at HKD 32 each. The company issued 18.321 million shares, with each lot consisting of 100 shares, raising a net proceeds of approximately HKD 531 million. As of the latest update, the stock fell 9.69% to HKD 28.9, with a trading volume of HKD 75.6697 million.

According to its prospectus, HANXBIO-B is a biotechnology company with proprietary expertise in structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline, including one core product and nine other candidate products. Among them are three oncology-focused clinical-stage candidates: the core product HX009, along with key products HX301 and HX044. Additionally, there are seven preclinical-stage candidates, including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets.

Public data indicates that HANXBIO-B's core product, HX009, is a bispecific antibody fusion protein targeting both CD47 and PD-1. According to a Frost & Sullivan report, as of the latest practicable date, HX009's clinical trial progress is globally leading among similar CD47-targeting bispecific antibody/bifunctional fusion protein products.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161099145?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 09:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161099145","market":"hk","top_or_hot":-1,"title":"HANXBIO-B (03378) Debuts with 9.69% Drop in Early Trading; Core Product HX009 Undergoes Three Clinical Trials in China","media":"Stock News","content":"<p>HANXBIO-B (03378) made its market debut today, with shares priced at HKD 32 each. The company issued 18.321 million shares, with each lot consisting of 100 shares, raising a net proceeds of approximately HKD 531 million. As of the latest update, the stock fell 9.69% to HKD 28.9, with a trading volume of HKD 75.6697 million.</p>\n<p>According to its prospectus, HANXBIO-B is a biotechnology company with proprietary expertise in structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline, including one core product and nine other candidate products. Among them are three oncology-focused clinical-stage candidates: the core product HX009, along with key products HX301 and HX044. Additionally, there are seven preclinical-stage candidates, including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets.</p>\n<p>Public data indicates that HANXBIO-B's core product, HX009, is a bispecific antibody fusion protein targeting both CD47 and PD-1. According to a Frost & Sullivan report, as of the latest practicable date, HX009's clinical trial progress is globally leading among similar CD47-targeting bispecific antibody/bifunctional fusion protein products.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B (03378) Debuts with 9.69% Drop in Early Trading; Core Product HX009 Undergoes Three Clinical Trials in China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B (03378) Debuts with 9.69% Drop in Early Trading; Core Product HX009 Undergoes Three Clinical Trials in China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-23 09:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HANXBIO-B (03378) made its market debut today, with shares priced at HKD 32 each. The company issued 18.321 million shares, with each lot consisting of 100 shares, raising a net proceeds of approximately HKD 531 million. As of the latest update, the stock fell 9.69% to HKD 28.9, with a trading volume of HKD 75.6697 million.</p>\n<p>According to its prospectus, HANXBIO-B is a biotechnology company with proprietary expertise in structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline, including one core product and nine other candidate products. Among them are three oncology-focused clinical-stage candidates: the core product HX009, along with key products HX301 and HX044. Additionally, there are seven preclinical-stage candidates, including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets.</p>\n<p>Public data indicates that HANXBIO-B's core product, HX009, is a bispecific antibody fusion protein targeting both CD47 and PD-1. According to a Frost & Sullivan report, as of the latest practicable date, HX009's clinical trial progress is globally leading among similar CD47-targeting bispecific antibody/bifunctional fusion protein products.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1161099145","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161099145","pubTimestamp":1766454020,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HANXBIO-B (03378) made its market debut today, with shares priced at HKD 32 each. The company issued 18.321 million shares, with each lot consisting of 100 shares, raising a net proceeds of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B","BK1535":"港口运输股","BK1173":"海港与服务"},"translate_title":"汉克生物-B(03378)首次亮相，早盘下跌9.69%；核心产品HX009在中国进行三项临床试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"HANXBIO-B (03378) made its market debut today, with shares priced at HKD 32 each. The company issued 18.321 million shares, with each lot consisting of 100 shares, raising a net proceeds of approximately HKD 531 million. As of the latest update, the stock fell 9.69% to HKD 28.9, with a trading volume of HKD 75.6697 million.\nAccording to its prospectus, HANXBIO-B is a biotechnology company with proprietary expertise in structural biology, translational medicine, and clinical development. Since 2016, the company has developed a product pipeline, including one core product and nine other candidate products. Among them are three oncology-focused clinical-stage candidates: the core product HX009, along with key products HX301 and HX044. Additionally, there are seven preclinical-stage candidates, including antibody-drug conjugates, bispecific antibodies, and monoclonal antibodies targeting autoimmune and oncology markets.\nPublic data indicates that HANXBIO-B's core product, HX009, is a bispecific antibody fusion protein targeting both CD47 and PD-1. According to a Frost & Sullivan report, as of the latest practicable date, HX009's clinical trial progress is globally leading among similar CD47-targeting bispecific antibody/bifunctional fusion protein products.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161099145","isCrawlerRequest":true}